Robert B. Davidson, Esq., FCIArb, a retired partner of a major international law firm and the Executive Director of JAMS Arbitration Practice, is now one of the country’s foremost commercial arbitrators and mediators. His IP experience as a litigator includes the trial of two Markman hearings and the representation of other clients in patent related claims. He has acted as sole arbitrator of a patent infringement claim (validity and infringement) and as an arbitrator in additional cases in which patent rights or claims were at issue. He has mediated patent and trademark disputes relating to proprietary software, electric toys and clothing, and has also mediated music copyright infringement disputes.
- Acted as sole arbitrator in patent infringement arbitration (validity and infringement) involving a process used in the automotive industry. The matter arose out of a private agreement between competitors to arbitrate future patent disputes in accordance with detailed procedural stipulation (ad hoc arbitration using AAA Patent Arbitration Rules)
- Chair of panel involving alleged breach of license agreement brought by inventor against pharmaceutical company; allegations were that licensee either failed to exploit the invention as promised or abandoned the promised commercialization (ICDR Rules)
- Party-appointed arbitrator on Tribunal involving alleged breach of license agreement between European drug company and U.S. pharmaceutical company; allegations that licensee failed to engage in good clinical practices in attempts to obtain drug approval by U.S. and European regulators; Netherlands Arbitration Institute Rules
- Party-appointed arbitrator in dispute involving alleged breach of license agreement under which a U.S. pharmaceutical company licensed a drug to a Japanese licensee who agreed to perform the needed testing and to obtain approval for the marketing of the pharmaceutical in Japan
- Chair of ICDR panel involving dispute over a license agreement between a pharmaceutical company-licensor and a large European pharmaceutical company-licensee that agreed to obtain FDA approval for the marketing of the pharmaceutical in the United States. Licensor alleged breach by reason of the licensee's alleged failure to conduct Phase 3 trial properly
- Chair of panel involving dispute over license agreement between Swedish patent holder and U.S. company involving alleged breach of contract to seek U.S. agency approval and then purchase of devices used to secure ocean-going shipping containers (CPR Non-Administered Rules)
- When in practice, acted as trial counsel in two Markman hearings, one relating to a patent for a means of connecting a two-piece brushgear used in direct current electric motors, and another involving a patent for the delivery of audio and video signals via a hybrid fiber optic- coaxial cable network; also represented holder of patent for a configuration of satellites in geostationary orbits used for the continuous transmission of radio signals.